DeepMed Research

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

Phase 1

Conditions: AML

Interventions: Drug: Cytarabine
Drug: all-trans retinoic acid
Drug: Arsenic Trioxide

First Posted Date: 2017-01-25

Last Posted Date: 2020-03-20

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 80

Registration Number: NCT03031249

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Efficacy and Safety of Chidamide in CBF Leukemia

Phase 1

Conditions: AML

Interventions: Drug: Cytarabine
Drug: Chidamide

First Posted Date: 2017-01-25

Last Posted Date: 2019-03-22

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 250

Registration Number: NCT03031262

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Phase 1

Completed

Conditions: Relapse
Lymphomas Non-Hodgkin's B-Cell

Interventions: Biological: CD19 CAR T cells

First Posted Date: 2017-01-24

Last Posted Date: 2022-01-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT03029338

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

Phase 3

Recruiting

Conditions: AML

Interventions: Drug: Daunomycin and Cytarabine (DA Regimen)
Drug: Daunomycin and Cytarabine (Intermediate Dose of DA Regimen)

First Posted Date: 2017-01-13

Last Posted Date: 2023-10-05

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 1100

Registration Number: NCT03021330

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Efficacy of Decitabine in Clearance of MRD

Phase 1

Suspended

Conditions: AML

Interventions: Drug: Decitabine

First Posted Date: 2017-01-13

Last Posted Date: 2019-03-22

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 300

Registration Number: NCT03021395

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukaemia Recurrent
Acute Lymphoblastic Leukemia, Adult B-Cell

Interventions: Biological: CD19 CAR T cells

First Posted Date: 2016-11-29

Last Posted Date: 2019-07-09

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT02975687

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML

Phase 2

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Physician-Directed Regimens without Cyclophosphamide
Drug: Idarubicin
Drug: Cytarabine
Drug: Cyclophosphamide

First Posted Date: 2016-10-18

Last Posted Date: 2019-03-22

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 60

Registration Number: NCT02937662

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Phase 4

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: Thalidomide
Drug: Doxorubicin
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Cisplatin
Drug: Vincristine
Drug: Rituximab

First Posted Date: 2016-08-08

Last Posted Date: 2019-06-14

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 55

Registration Number: NCT02858804

Locations: 🇨🇳
Shuhua Yi, Tianjin, China

Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia

Phase 4

Conditions: Waldenström Macroglobulinemia

Interventions: Other: conventional chemotherapy
Other: autologous stem cell transplantation

First Posted Date: 2016-07-26

Last Posted Date: 2016-07-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 70

Registration Number: NCT02844361

Locations: 🇨🇳
Shuhua Yi, Tianjin, China

The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM

Phase 4

Conditions: Waldenström Macroglobulinemia

Interventions: Drug: Thalidomide

First Posted Date: 2016-07-26

Last Posted Date: 2016-07-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 44

Registration Number: NCT02844309

Locations: 🇨🇳
Shuhua Yi, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy